A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs BMS 986165 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms PAISLEY
- Sponsors Bristol-Myers Squibb
- 27 Jun 2019 According to a Lupus Research Alliance media release, Bristol-Myers Squibb is delighted to expand the existing collaboration with Lupus Therapeutics to include both systemic lupus erythematosus and lupus nephritis.
- 27 Jun 2019 According to a Lupus Research Alliance media release, Lupus Clinical Investigators Network (LuCIN) sites are part of this ongoing study.
- 25 May 2018 Planned number of patients changed from 400 to 360.